2 weeks Ago By ABMN Staff
Shares of Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX – Get Free Report ) hit a new 52-week high during trading on Thursday after Citigroup raised their price target on the stock from $70.00 to $74.
00. Citigroup currently has a buy rating on the stock. Crinetics Pharmaceuticals traded as high as $62.
53 and last traded at $62.00, with a volume of 320685 shares. The stock had previously closed at $58.
92. CRNX has been the topic of a number of other reports. JMP Securities restated a “market outperform” rating and set a $80.
00 price target on shares of Crinetics Pharmaceuticals in a research note on Friday, September 27th. Oppenheimer reissued an “outperform” rating and set a $73.00 target price (down previously from $74.
00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $90.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th.
Finally, HC Wainwright boosted their price target on shares of Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday.
One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $70.
18. Check Out Our Latest Report on CRNX Insider Transactions at Crinetics Pharmaceuticals Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in CRNX. Comerica Bank purchased a new stake in Crinetics Pharmaceuticals during the first quarter worth approximately $33,000.
Quest Partners LLC acquired a new stake in Crinetics Pharmaceuticals during the second quarter worth approximately $42,000. Values First Advisors Inc. acquired a new stake in Crinetics Pharmaceuticals during the third quarter worth approximately $84,000.
Allspring Global Investments Holdings LLC purchased a new stake in shares of Crinetics Pharmaceuticals during the 3rd quarter worth approximately $91,000. Finally, KBC Group NV boosted its holdings in shares of Crinetics Pharmaceuticals by 22.8% in the 3rd quarter.
KBC Group NV now owns 2,193 shares of the company’s stock valued at $112,000 after buying an additional 407 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.
Crinetics Pharmaceuticals Stock Performance The stock’s 50-day moving average is $54.88 and its 200 day moving average is $51.15.
The stock has a market capitalization of $4.77 billion, a PE ratio of -15.99 and a beta of 0.
62. Crinetics Pharmaceuticals ( NASDAQ:CRNX – Get Free Report ) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.
96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.05).
During the same quarter in the prior year, the business posted ($1.01) EPS. Analysts expect that Crinetics Pharmaceuticals, Inc.
will post -3.72 earnings per share for the current year. About Crinetics Pharmaceuticals ( Get Free Report ) Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. See Also Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
